Dosage form for treating severe asthma

Patent metadata

Field	Value
Publication number	US-12083144-B2
Application number	US-202117466454-A
Country	US
Kind code	B2
Filing date	Sep 3, 2021
Priority date	Feb 24, 2017
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.

First claim

We claim:

1. A method of treating severe asthma in a patient, comprising administering to the patient a composition comprising:
a corticosteroid; and
a nucleic acid or an analog thereof able to decrease IRF5 expression in the patient in an amount effective to reduce IRF5 activity to a level effective to treat one or more symptoms of asthma in the patient.

2. The method of claim 1 , wherein the patient displays a Th2 lo immune profile.

3. The method of claim 1 , wherein the patient has corticosteroid-insensitive asthma.

4. The method of claim 1 , wherein the nucleic acid or analog thereof is an antisense reagent.

5. The method of claim 1 , wherein the nucleic acid or analog thereof is an interfering nucleic acid.

6. The method of claim 5 , wherein the interfering nucleic acid is an RNA.

7. The method of claim 6 , wherein the RNA is a microRNA reagent or a small interfering RNA reagent.

8. The method of claim 1 , wherein the composition is administered through delivery to the patient's respiratory tract.

9. The method of claim 8 , wherein the composition is administered daily.

10. The method of claim 8 , wherein the composition is administered with a metered dose inhaler.

11. The method of claim 8 , wherein the composition is administered with a nebulizer.

12. The method of claim 1 , wherein the nucleic acid or an analog thereof has the sequence of SEQ ID NO: 7 or a sequence complementary thereto or the sequence of SEQ ID NO: 8 or a sequence complementary thereto.

13. An aerosolizable or nebulizable composition comprising:
a pharmaceutically-acceptable carrier;
a corticosteroid; and
a nucleic acid or an analog thereof able to decrease IRF5 expression in a patient in an amount effective to reduce IRF5 activity to a level effective to treat one or more symptoms of asthma in the patient.

14. The composition of claim 13 , wherein the composition has a particle size in a range of 20 μm to 500 μm and is configured to be administered by inhalation.

15. The composition of claim 13 , wherein the nucleic acid or analog thereof is an antisense reagent.

16. The composition of claim 13 , wherein the nucleic acid or an analog thereof is an interfering nucleic acid.

17. The composition of claim 16 , wherein the interfering nucleic acid is an RNA.

18. The composition of claim 17 , wherein the interfering nucleic acid is a microRNA reagent or a small interfering RNA reagent.

19. The composition of claim 13 , wherein the nucleic acid or an analog thereof has the sequence of SEQ ID NO: 7 or a sequence complementary thereto, or the sequence of SEQ ID NO: 8 or a sequence complementary thereto.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Ray Anuradha
• Ray Prabir
• Wenzel Sally Ellen
• Oriss Timothy B

Classifications

• A61P11/06

  Antiasthmatics · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/573

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• A61K31/713 Primary

  Double-stranded nucleic acids or oligonucleotides · CPC title